Key result
Therapeutically refractory hypertension affects ~10% of patients with hypertension, driven by intolerance or fixed resistance.
Why the study?
A subset of hypertensive patients, possibly 10% or more, fail to respond satisfactorily to established medical treatments, necessitating investigation of causative factors and management strategies.
Answers are grounded in this paper and cite their sources.
Highlights refractory hypertension burden in practice; leaves open optimal strategies for intolerance or resistance.
Article1 November 1958THERAPEUTICALLY "REFRACTORY" HYPERTENSION: CAUSATIVE FACTORS, AND MEDICAL MANAGEMENT WITH CHLOROTHIAZIDE AND OTHER AGENTSRICHARD E. LEE, ARTHUR W. SELIGMANN, MELVA A. CLARK, NEMAT O. BORHANI, JOHN T. QUEENAN, MAUREEN E. O'BRIENRICHARD E. LEESearch for more papers by this author, ARTHUR W. SELIGMANNSearch for more papers by this author, MELVA A. CLARKSearch for more papers by this author, NEMAT O. BORHANISearch for more papers by this author, JOHN T. QUEENANSearch for more papers by this author, MAUREEN E. O'BRIENSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-49-5-1129 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONAlthough the great majority of hypertensive patients can be managed effectively with presently established medical programs,1, 2instances of failure to respond to treatment in a completely satisfactory manner are not uncommon. In our experience, such patients may include as many as 10% or more of the hypertensive population.3Major reasons for such "refractoriness" are probably at least twofold: (1) predisposition to intolerance of drug side-effects that prevents use of antihypertensive agents in adequate amounts, and (2) perhaps a more fixed or resistant type of blood pressure elevation that is not amenable to the therapy employed. Within the last...Bibliography1. Wilkins RW: New drug therapies in arterial hypertension, Ann. Int. Med. 37: 1144-1155, 1952. LinkGoogle Scholar2. MoyerHeiderPeveyFork JHCKRV: Effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function, Am. J. Med. 24: 177-192, 1958. CrossrefMedlineGoogle Scholar3. LeeSeligmannGoebelFultonClark REAMDLAMA: Reserpinehydralazine combination therapy of hypertensive disease, with hydralazine in doses generally below the "toxic range," Ann. Int. Med. 44: 456-465 (Mar.) 1956. LinkGoogle Scholar4. FreisWilson EDIM: Potentiating effect of chlorothiazide (Diuril) in combination with antihypertensive agents, preliminary report, M. Ann. District of Columbia 26: 468 (Sept.) 1957. MedlineGoogle Scholar5. HollanderWilkins WRW: Chlorothiazide: a new type of drug for the treatment of hypertension, Boston M. Quart. 8: 69-75 (Sept.) 1957. Google Scholar6. Wilkins RW: New drugs for hypertension with special reference to chlorothiazide, New England J. Med. 257: 1026-1030 (Nov.) 1957. CrossrefMedlineGoogle Scholar7. FreisWankoWilsonParrish EDAIMAE: Treatment of essential hypertension with chlorothiazide (Diuril): its use alone and combined with other antihypertensive agents, J. A. M. A. 166: 137-140, 1958. CrossrefMedlineGoogle Scholar8. HeiderDennisMoyer CEJH: Chlorothiazide potentiation of ganglionic blockade in patients with hypertension, Ann. New York Acad. Sc. 71: 456-464, 1958. CrossrefMedlineGoogle Scholar9. WilkinsHollanderChobanian RWWAV: Chlorothiazide in hypertension: studies in its mode of action (lists side effects, factors of Na loss, etc.), Ann. New York Acad. Sc. 71: 465-472, 1958. CrossrefMedlineGoogle Scholar10. HollanderChobanian WAV: The mode of action of chlorothiazide and mercurial diuretics as antihypertensive drugs, Proc. Am. Soc. Clin. Investigation 32: (May) 1958. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication July 7, 1958.From the Department of Medicine, Cornell University Medical Center, and the New York Hospital, New York, N. Y.Requests for reprints should be addressed to Richard E. Lee, M.D., Department of Medicine, The New York Hospital, 525 East Sixty-eighth Street, New York 21, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byResistant Hypertension: Novel InsightsDefinitions of Resistant Hypertension and Epidemiology of Resistant HypertensionRefractory versus resistant hypertensionRefractory and Resistant Hypertension: Antihypertensive Treatment Failure versus Treatment ResistanceResistant or Refractory Hypertension: Are They Different?A review of the benzothiadiazine derivatives in relation to cardiovascular diseaseA Comparison of the Side Effects and Antihypertensive Potency of Chlorothiazide and HydrochlorothiazideBehandlung der benignen und malignen HypertonieTreatment of hypertensionUSE OF TRIMETHIDINIUM METHOSULFATE (A NEW GANGLIONIC BLOCKING AGENT) IN THE TREATMENT OF HYPERTENSION*†‡NEMAT O. BORHANI, M.D.Antihypertensive Wirkung der Diuretica 1 November 1958Volume 49, Issue 5Page: 1129-1137KeywordsAntihypertensive drug therapyBlood pressureEdemaGastroenterology and hepatologyHospital medicineHypertensionNausea ePublished: 1 December 2008 Issue Published: 1 November 1958 PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Jr. et al. (1958) conducted a review in Refractory hypertension. Chlorothiazide and other agents was evaluated. Therapeutically refractory hypertension may affect 10% or more of the hypertensive population, driven by medication intolerance or fixed resistance to therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: